<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01968135</url>
  </required_header>
  <id_info>
    <org_study_id>13-1702</org_study_id>
    <nct_id>NCT01968135</nct_id>
  </id_info>
  <brief_title>Does Concomitant Use of Combined Oral Hormonal Steroids Stop Bleeding in Women Using Etonogestrel Implants (Implanon/Nexplanon®)?: A Randomized Controlled Study</brief_title>
  <official_title>Does Concomitant Use of Combined Oral Hormonal Steroids Stop Bleeding in Women Using Etonogestrel Implants (Implanon/Nexplanon®)?: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The specific aims are to determine if more women using Etonogestrel (ENG) contraceptive
      implants who report a bleeding-spotting episode of at least seven days will stop bleeding
      within 3 days of beginning a 14-day course of combined oral hormonal steroids, as compared to
      women receiving 14 days of placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ENG contraceptive implant (Implanon/Nexplanon®), is a silicone- free, single rod
      subdermal contraceptive implant that contains 68 mg of etonogestrel, is approved for use for
      three years, and is one of the most effective forms of contraception available (1). ENG
      contraceptive implants are easily inserted and removed (1,2), offer quick return to fertility
      (2), are cost-effective and cost-saving (3,4) and offer non-contraceptive benefits such as
      improvement in pain for patients with complaints of dysmenorrhea (5).

      Hypothesis: Women using ENG contraceptive implants who report a bleeding-spotting episode of
      at least seven days will be more likely to stop bleeding within 3 days of beginning a 14-day
      course of combined oral hormonal steroids compared to women receiving 14 days of placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cessation of Vaginal Bleeding</measure>
    <time_frame>At day 3 of 14 day course of study drug</time_frame>
    <description>Proportion of women in each group who stopped bleeding during therapy and continued to report no bleeding at the end of the 14-day treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Days Until Temporary Interruption of Bleeding During Therapy Occurred</measure>
    <time_frame>over the 14 day course of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days Without Bleeding During Therapy</measure>
    <time_frame>Over the 14 day course of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days to Recurrence of Bleeding After Discontinuation of Therapy</measure>
    <time_frame>Up to six months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Uterine Hemorrhage</condition>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Sugar Pill</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined Oral Contraceptive Pill</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combined Oral Contraceptive Pill</intervention_name>
    <description>150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill</description>
    <arm_group_label>Combined Oral Contraceptive Pill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Sugar Pill</intervention_name>
    <description>Placebo Sugar Pill</description>
    <arm_group_label>Sugar Pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All female

          -  English or Spanish speaking women

          -  between the ages of 18-44

          -  using an ENG contraceptive implant who complain of bothersome bleeding and have a
             current bleeding episode of at least seven days will be invited to participate.

        Exclusion Criteria:

          -  Category 3 or 4 contraindications to estrogen therapy according to the Centers for
             Disease Control 2010 Medical Eligibility Criteria.

          -  Category 3 contraindications: less than 1 month postpartum if breastfeeding, less than
             21 days postpartum if not breastfeeding, history of Deep Vein Thrombosis (DVT)
             /Pulmonary Embolism (PE) not on anticoagulant therapy and no risk factors, Deep venous
             thrombosis/Pulmonary Embolus on established anticoagulant therapy and no risk factors,
             history of malabsorptive bariatric surgery, greater than or equal to months post
             peripartum cardiomyopathy with normal to mildly impaired cardiac function, greater
             than or equal to 35 years old with less than 15 cigarettes smoked per day, multiple
             risk factors for arterial cardiovascular disease, adequately controlled hypertension,
             blood pressure 140-159/90-99 mm Hg, migraines without aura less than 35 years old,
             past breast cancer and no evidence of recurrent disease for 5 years, diabetes with
             retinopathy, neuropathy, nephropathy (category 3 or 4 depending on severity), diabetes
             greater than 20 years duration or associated with other vascular disease, medically
             treated symptomatic gallbladder disease or current symptomatic gallbladder disease,
             past combined oral contraceptive pill related cholestasis, acute viral hepatitis,
             hepatocellular adenoma, hepatoma, use of ritonavir-boosted protease inhibitors,
             anticonvulsant therapy use including phenytoin, carbamazepine, barbiturates,
             primidone, topiramate, oxcarbazepine, and lamotrigine, use of Rifampicin,

          -  Category 4 contraindications: less than 6 months post peripartum cardiomyopathy with
             normal to mildly impaired cardiac function, any time following peripartum
             cardiomyopathy with moderately to severely impaired cardiac function, greater than or
             equal to 35 years old with greater than 15 cigarettes smoked per day, multiple risk
             factors for arterial cardiovascular disease, blood pressure greater than or equal to
             160/100 mm Hg, high risk for recurrent DVT/PE, acute DVT/PE, DVT/PE and on established
             anticoagulant therapy with greater than or equal to 1 risk factor for recurrent
             DVT/PE, major surgery/prolonged immobilization, known thrombogenic mutations, current
             and history of ischemic heart disease, history of stroke, complicated valvular heart
             disease, systemic lupus erythematosus (SLE) with positive or unknown antiphospholipid
             antibodies, migraines without aura greater than or equal to 35 years old, migraines
             with aura at any age, current breast cancer, complicated solid organ transplantation

          -  Body mass index (BMI) greater than 35.

          -  A systolic blood pressure greater than 135 on more than 2 occasions. assuring the
             measurements are separated by an interval of at least 15 minutes.

          -  A diastolic blood pressure greater than 85 on more than 2 occasions. assuring the
             measurement are separated by an interval of at least 15 minutes.

          -  A positive pregnancy test.

          -  A positive chlamydia test.

          -  Unable or unwilling to swallow pills.

          -  A medical condition deemed severed by a physician investigator.

          -  A participant taking a liver enzyme inducing drug.

          -  A known allergy to levonorgestrel or ethinyl estradiol.

          -  An abnormal speculum exam (i.e. bleeding ectropion or cervical mass).

          -  Does not meet appropriate cervical cytology screening guidelines.

          -  Cervical procedure done in the past 3 months.

          -  On a concurrent hormonal contraceptive and unwilling to discontinue.

          -  Breast lesions
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maryam Guiahi, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2013</study_first_submitted>
  <study_first_submitted_qc>October 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2013</study_first_posted>
  <results_first_submitted>December 22, 2015</results_first_submitted>
  <results_first_submitted_qc>April 1, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 5, 2016</results_first_posted>
  <last_update_submitted>April 1, 2016</last_update_submitted>
  <last_update_submitted_qc>April 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Uterine Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Etonogestrel</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Contraceptives, Oral, Combined</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Women were invited to participate after being seen at one of our institution's clinics with the complaint of bothersome bleeding during use of etonogestrel implant, or after responding to advertisements posted on the internet, in the local newspaper, or around public venues. Women were enrolled and followed from November 2013 - December 2014.</recruitment_details>
      <pre_assignment_details>Interested women were screened by phone and subsequently invited for a screening visit. At this visit they were assessed for eligibility based on the specified inclusion/exclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sugar Pill</title>
          <description>Placebo Sugar Pill
Placebo Sugar Pill: Placebo Sugar Pill</description>
        </group>
        <group group_id="P2">
          <title>Combined Oral Contraceptive Pill</title>
          <description>150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill
Combined Oral Contraceptive Pill: 150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sugar Pill</title>
          <description>Placebo Sugar Pill
Placebo Sugar Pill: Placebo Sugar Pill</description>
        </group>
        <group group_id="B2">
          <title>Combined Oral Contraceptive Pill</title>
          <description>150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill
Combined Oral Contraceptive Pill: 150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.4" spread="4.8"/>
                    <measurement group_id="B2" value="21.4" spread="3"/>
                    <measurement group_id="B3" value="21.9" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.2" spread="2.9"/>
                    <measurement group_id="B2" value="23.3" spread="3.5"/>
                    <measurement group_id="B3" value="23.2" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total days of current bleeding episode</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.6" spread="44.6"/>
                    <measurement group_id="B2" value="30.3" spread="37.7"/>
                    <measurement group_id="B3" value="39.9" spread="41.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cessation of Vaginal Bleeding</title>
        <description>Proportion of women in each group who stopped bleeding during therapy and continued to report no bleeding at the end of the 14-day treatment period.</description>
        <time_frame>At day 3 of 14 day course of study drug</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill</title>
            <description>Placebo Sugar Pill
Placebo Sugar Pill: Placebo Sugar Pill</description>
          </group>
          <group group_id="O2">
            <title>Combined Oral Contraceptive Pill</title>
            <description>150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill
Combined Oral Contraceptive Pill: 150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill</description>
          </group>
        </group_list>
        <measure>
          <title>Cessation of Vaginal Bleeding</title>
          <description>Proportion of women in each group who stopped bleeding during therapy and continued to report no bleeding at the end of the 14-day treatment period.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days Until Temporary Interruption of Bleeding During Therapy Occurred</title>
        <time_frame>over the 14 day course of study drug</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill</title>
            <description>Placebo Sugar Pill
Placebo Sugar Pill: Placebo Sugar Pill</description>
          </group>
          <group group_id="O2">
            <title>Combined Oral Contraceptive Pill</title>
            <description>150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill
Combined Oral Contraceptive Pill: 150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Until Temporary Interruption of Bleeding During Therapy Occurred</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="5" upper_limit="14"/>
                    <measurement group_id="O2" value="5" lower_limit="1" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days Without Bleeding During Therapy</title>
        <time_frame>Over the 14 day course of study drug</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill</title>
            <description>Placebo Sugar Pill
Placebo Sugar Pill: Placebo Sugar Pill</description>
          </group>
          <group group_id="O2">
            <title>Combined Oral Contraceptive Pill</title>
            <description>150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill
Combined Oral Contraceptive Pill: 150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Without Bleeding During Therapy</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="0" upper_limit="11"/>
                    <measurement group_id="O2" value="9" lower_limit="1" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days to Recurrence of Bleeding After Discontinuation of Therapy</title>
        <time_frame>Up to six months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill</title>
            <description>Placebo Sugar Pill
Placebo Sugar Pill: Placebo Sugar Pill</description>
          </group>
          <group group_id="O2">
            <title>Combined Oral Contraceptive Pill</title>
            <description>150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill
Combined Oral Contraceptive Pill: 150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days to Recurrence of Bleeding After Discontinuation of Therapy</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="3" upper_limit="87"/>
                    <measurement group_id="O2" value="5.5" lower_limit="1" upper_limit="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sugar Pill</title>
          <description>Placebo Sugar Pill
Placebo Sugar Pill: Placebo Sugar Pill</description>
        </group>
        <group group_id="E2">
          <title>Combined Oral Contraceptive Pill</title>
          <description>150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill
Combined Oral Contraceptive Pill: 150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chanel Mansfield</name_or_title>
      <organization>University of Colorado Denver</organization>
      <phone>303-724-6501</phone>
      <email>chanel.mansfield@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

